All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Ana Zelic Kerep from the Experimental Transplantation and Immunology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA, and colleagues compared the revised 2014 NIH chronic graft-versus-host disease (cGvHD) severity scoring criteria to the 2005 NIH cGvHD criteria in order to assess the impact of changes to the original NIH cGvHD guideline. The study was published ahead of print on 8 August 2018 in Bone Marrow Transplantation.
In conclusion, this study showed that the revised 2014 NIH cGvHD staging criteria presented milder organ involvement scores for liver and lung involvement, which resulted in overall milder global scores. The authors added that “this score shift could, in some cases, steer the clinician toward less-aggressive therapy.” They further stated that “the 2014 NIH cGvHD scoring criteria in continuing efforts to develop better classification systems more firmly encompassing the biological heterogeneity of this disease.”
Subscribe to get the best content related to GvHD delivered to your inbox